Skip to main content
MGX
NASDAQ Life Sciences

FDA Clears IND for One-Time Hemophilia A Gene Editing Therapy; Cash Runway Into 2028

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$0.72
Mkt Cap
$26.444M
52W Low
$0.6
52W High
$2.275
52W Position info
20% above low
Off High info
68% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

MGX sits 20% above its 52-week low of $0.6.

Summary

The FDA cleared Metagenomi's IND for MGX-001, its wholly owned hemophilia A gene editing program, letting the company start its first-in-human INTEGR8 Phase 1/2 trial. That is the key de-risking step for a micro-cap with no revenue-generating product; the program now moves from preclinical to clinic. Management plans to start INTEGR8 in the first half of 2027 and report initial safety, tolerability and FVIII activity data in the second half of 2027. Cash and marketable securities stood at $101.7 million on September 30, down from $160.8 million at year-end, with runway guided into 2028 — enough to fund the trial start but not its readout without more capital. Q3 R&D spend fell to $17.5 million from $25.3 million a year earlier, the net loss was $21.1 million, and revenue was $2.18 million. Additional preclinical MGX-001 data will be presented at ASH on December 14, 2026.

At the time of this announcement, MGX was trading at $0.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.4M. The 52-week trading range was $0.60 to $2.28. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

MGX - Latest Insights

MGX
Nov 10, 2026, 4:08 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.720
Real-time Price: $0.6917 info
Change: -$0.0283 (-4%) info
Market Cap: $26.15M info
MGX
Nov 10, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.720
Real-time Price: $0.6917 info
Change: -$0.0283 (-4%) info
Market Cap: $26.15M info
MGX
Aug 10, 2026, 4:12 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.20
Real-time Price: $0.6917 info
Change: -$0.5083 (-42%) info
Market Cap: $26.15M info
MGX
Aug 10, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.20
Real-time Price: $0.6917 info
Change: -$0.5083 (-42%) info
Market Cap: $26.15M info
MGX
Jun 05, 2026, 3:45 PM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.27
Real-time Price: $0.6917 info
Change: -$0.5783 (-46%) info
Market Cap: $26.15M info